BOEHRINGER-INGELHEIM
9.5.2023 14:36:33 CEST | Business Wire | Press release
Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas. The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte. Ltd. (Enleofen), with a goal to improve patient outcomes.
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis, or scarring, of various organs and tissues. It can be triggered by different factors (such as infections, inflammation, autoimmune disorders, degenerative diseases, tumors, and injury), can cause organ dysfunction/failure, and affect the quality of life and survival of patients. Some examples of fibrotic diseases are, systemic sclerosis, graft-versus-host disease as well as heart, lung, liver, and kidney fibrosis. Current treatments have led to progress in some areas, however fibrotic diseases remain to be a leading cause of morbidity/mortality and account for more than one third of deaths worldwide.
IL-11 plays a key role in fibrosis across multiple organs and pre-clinical studies have shown that anti-IL-11 treatment has the potential to stop – and even reverse fibrosis – in different fibrotic diseases. Boehringer Ingelheim joined forces with Enleofen, a leader in IL-11 biology, in 2020.
“The initiation of this trial is an important milestone for Boehringer Ingelheim and brings us closer to achieving our aim of transforming lives of people living with fibrotic diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “The effects shown for anti-IL-11 preclinically are impressive and could, if confirmed in the clinic, herald a dramatic advance in the treatment of fibrotic diseases.”
“Enleofen is very excited to see the IL-11 inhibitor partnership with Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D, moving forward into the clinic to address unmet patient needs,” said Prof Stuart Cook, co-founder of Enleofen and Tanoto Foundation Professor of Cardiovascular Medicine at the SingHealth Duke-NUS Academic Medical Centre and the Cardiovascular & Metabolic Disorders Programme at Duke-NUS Medical School, Singapore.
The IL-11 program complements Boehringer Ingelheim’s clinical fibrotic disease pipeline portfolio which includes BI 1015550, a phosphodiesterase 4B (PDE4B) inhibitor, under investigation in two Phase III randomized, double-blind, placebo-controlled trials—FIBRONEER™-IPF (NCT05321069) and FIBRONEER™-ILD (NCT05321082)—to investigate the efficacy, safety and tolerability of BI 1015550 over at least 52 weeks in patients with IPF and in patients with other progressive fibrosing ILDs and several other clinical stage programs.
###
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com
About Enleofen
Enleofen is a Singapore-based biotech company developing first-in-class antibody therapeutics for the treatment of fibro-inflammatory human diseases. The initial discovery science and drug target validation was carried out by founders Stuart Cook and Sebastian Schäfer at the National Heart Centre Singapore at SingHealth and Duke-NUS Medical School and was subsequently licensed to Enleofen. Since 2017, the company has invested extensively in target validation, drug development, and preclinical studies, with the support of experienced international life sciences executives and investors, including founding directors Jeffrey Lu and Andrew Khoo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005762/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs to Acquire U.S. Rare Earth and Critical Minerals Company Powering Defense and National Security14.5.2026 14:01:00 CEST | Press release
Proposed Acquisition Would Position Mobix Labs Inside Strategic U.S. Supply Chains Powering Defense, National Security, and AI Infrastructure Mobix Labs, Inc. (Nasdaq: MOBX) today announced it has signed a non-binding Letter of Intent to acquire Special Project Delivery LLC ("SPD"), a strategic infrastructure platform building sovereign U.S. supply chains for rare earth elements, critical minerals, and energy storage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514342224/en/ U.S.A F-35 Lightning II The proposed acquisition would expand Mobix Labs — already a supplier to advanced U.S. and allied defense and aerospace systems — directly into one of the world's most strategically important industrial sectors. Key Facts at a Glance~418 kilogramsof rare earth materials are estimated to be used in each F-35 Lightning II. ~4,500 kilogramsof rare earth materials are estimated to be used in each Virginia-class nuclear submarine
Enterprise AI Hits the Wall: NTT DATA Research Reveals Growing Privacy and Sovereignty Barriers14.5.2026 14:00:00 CEST | Press release
Demands for privacy and sovereignty expose limits of architectures built for centralized and borderless data flows. Data jurisdiction has become a core design parameter, shifting away from globally integrated systems to regionally bounded architectures. Organizations that redesign early are gaining a measurable edge in AI readiness and scale. NTT DATA, a global leader in AI, digital business and technology services, today released new research showing that enterprise AI is outgrowing the architecture and infrastructure beneath it as data privacy and sovereignty requirements tighten. The research finds a widening split between enterprises that are redesigning AI for control, locality and security, and organizations still layering AI into environments that were not built to support these requirements. For years, enterprise architecture moved data across systems, clouds, applications and borders with increasing speed and efficiency. AI is exposing the limits of that model. Sensitive data
Mary Kay Launches Global Social Squad Program to Empower the Next Generation of Digital Beauty Leaders14.5.2026 14:00:00 CEST | Press release
A Global Program Connecting 70+ Emerging Creators Among Independent Beauty Consultants with Digital Education, Mentorship, And Real‑World Beauty Brand Experience. Mary Kay Inc., a global leader in beauty and entrepreneurship, announces the launch of its Global Social Squad (GSS) Pilot Program – a groundbreaking initiative designed to empower Mary Kay Independent Beauty Consultants (IBCs) as dynamic digital brand advocates and next-generation social media storytellers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514978222/en/ The Global Social Squad ignites a diverse and talented group of 73 Mary Kay Independent Beauty Consultants with representation across 15 markets in four regions: North America, Asia Pacific, Latin America, and Europe. These digital leaders create engaging, high-quality content, participate in global campaign activations, and share practical social media strategies with their communities and other I
Vista Equity Partners Establishes Abu Dhabi Office14.5.2026 14:00:00 CEST | Press release
Securing Full Regulatory Authorization from ADGM deepens Vista’s commitment to the Middle East and expands the firm’s global platform for enterprise software investing Vista Equity Partners (“Vista”), a global technology investor that specializes in enterprise software, today announced the opening of its new office in Abu Dhabi within ADGM, the city’s international financial center. VEPM Middle East Limited has received full authorization from ADGM’s Financial Services Regulatory Authority (FSRA), enabling the firm to advise on investments and arrange deals in investments across the region. The Abu Dhabi office reflects Vista’s expanded strategic presence in the Middle East and the region’s increasingly central role in global technology investment and innovation. Established in 2013, ADGM has emerged as one of the world’s leading financial centers, connecting global investors with regional opportunities. Vista joins a growing community of leading global investment firms that have estab
Eighteen48 Partners Announces First Close of Eighteen48 Private Equity Fund I at €175 million14.5.2026 13:56:00 CEST | Press release
Eighteen48 Partners today announced the first close of Eighteen48 Private Equity Fund I (the “Fund”) at €175 million. The Fund, which is targeting €350 million, is focused on European middle-market buyout transactions sourced through Independent Sponsors. Since 2020 Eighteen48 Partners have deployed more than €200 million into this strategy, which aims to provide investors with diversified exposure to off-market sourced transactions. The first close was supported by significant re-up commitments from Eighteen48 clients as well as commitments from institutions, family offices and UHNWs, underscoring the strength of the firm’s platform, track record and experience as well as growing momentum in the Independent Sponsor space. Julien Sevaux, Founding Partner and CEO, commented: “We are increasingly excited by the opportunity in the growing independent sponsor segment of European private equity - a corner of the market we believe remains largely overlooked by investors yet offers compelling
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom